Skip to main content

Table 2 Correlation of TGase 2 over-expression with clinicopathologic variables in patients with resectable early-stage NSCLC

From: Transglutaminase 2 as an independent prognostic marker for survival of patients with non-adenocarcinoma subtype of non-small cell lung cancer

Variables

Total number

TGase 2 expression

p-value

  

Negative

Intermediate

Strong

 

Histology

     

Adenocarcinoma

193 (45)

74(38)

58(30)

61(32)

<0.001

Squamous carcinoma

198 (46)

155(78)

26(13)

17(9)

 

Others*

38 (9)

19(50)

9(24)

10(26)

 

Differentiation**

     

Well

61 (18)

41(67)

11(18)

9(15)

0.474

Moderate

200 (58)

122(61)

41(21)

37(19)

 

Poorly

87 (25)

47(54)

18(21)

22(25)

 

Gender

     

Male

324 (76)

206(64)

58(18)

60(19)

<0.001

Female

105 (24)

42(40)

35(33)

28(27)

 

Smoking

     

Nonsmoker

113 (26)

44(39)

35(31)

34(30)

<0.001

Ex-smoker

120 (28)

86(72)

15(13)

19(16)

 

Current Smoker

196 (46)

118(60)

43(22)

35(18)

 

T-stage***

     

1

81 (19)

40(50)

16(20)

25(31)

0.037

2

277 (65)

161(58)

67(24)

49(18)

 

3-4

70 (16)

47(67)

10(14)

13(19)

 

N-stage

     

0

257 (60)

148(58)

55(21)

54(21)

0.414

1

93 (22)

53(57)

17(18)

23(25)

 

2-3

79 (18)

47(60)

21(27)

11(14)

 

Recurrence event

     

No

259 (60)

165(64)

52(20)

42(16)

0.005

Yes

170 (40)

83(49)

41(24)

46(27)

 

Recurrence in male patients

     

No

203 (47)

141(69)

33(16)

29(14)

 

Yes

121 (28)

65(54)

25(21)

31(26)

0.011

Recurrence in female patients

     

No

56 (53)

24(42)

19(34)

13(23)

0.672

Yes

49 (47)

18(37)

16(33)

15(31)

 

Recurrence in patients with adenocarcinoma

     

No

102 (53)

43(42)

29(28)

30(29)

0.512

Yes

91 (47)

31(34)

29(32)

31(34)

 

Recurrence in patients with non-adenocarcinoma

     

No

157 (67)

122(78)

23(15)

12(8)

0.031

Yes

79 (33)

52(66)

12(15)

15(19)

 
  1. The significance was tested with Chi-square or Fisher's exact tests (p). The percentages for the variables are shown within parentheses.
  2. *Large cell lung cancer (13), adenosquamous carcinoma (9), mucoepidermoid carcinoma (8), sarcomatoid carcinoma (3), Pleomorphic carcinoma (2), lymphepithelioma-like carcinoma (1), adenoid cystic carcinoma (1), and basaloid cell carcinoma (1)
  3. **No information on the pathological differentiation status was available in 81 cases.
  4. ***No information on the T-stage was available in one case.